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INTRODUCTION 
 
Cardiovascular disease is an epidemic of modern society. Hypertension is 
one of the most common forms of cardiovascular disease the prevalence of which 
increases with age.  It is one of the most important public health problems and if 
left untreated can lead to serious morbidity and mortality from cardiac, 
cerebrovascular  and renal diseases. 
 
Metals constitute a major category of toxins that pose a significant threat 
to health through occupational as well as environmental exposures. One 
indication of their importance relative to other potential hazards is their ranking 
by the U.S Agency for Toxic Substances and Diseases Registry, which lists all 
hazards present in toxic waste sites according to their prevalence and the severity 
of their toxicity. The first, second, third and sixth hazards on the list are heavy 
metals; lead, mercury, arsenic and cadmium respectively (Howard Hu et.al 
2001.). 
 
Lead was probably one of the first metals to be produced by man being 
known since 3500 B.C., in agreement with archaeological discoveries done in 
Egypt. Lead poisoning is as ancient as Roman history. A strong association 
between blood lead level and the prevalence of hypertension was noted in the 
second National Health and Nutrition Examination Survey (NHANES II) 
conducted during 1976 and 1980 (Vupputuri et al 2003). Several clinical and 
laboratory observations are consistent with the hypothesis that high lead levels 
may be important in the development of primary hypertension in humans. Bagchi 
et al (2005) has demonstrated that elevated lead levels was associated with an 
increase in systolic BP in rats. 
 
 
The interest in blood lead levels as a potential risk factor for 
cardiovascular disease has ballooned in the last several years with numerous 
abstracts and research papers, multiple editorials, review articles being published 
regarding this issue. 
 
 
While some animal studies have found a positive association between 
blood lead levels and hypertension some others have come to an opposite 
conclusion (Shelkovnikov et al 2001). Thus the role of blood lead levels as a risk 
factor for systemic hypertension remains controversial and further studies 
regarding the pathogenesis of lead induced hypertension are needed.  
 
 
 
 
 
Similarly some human studies have found no correlation between blood 
lead levels and hypertension [Cheng et al 2001]. Instead they found correlation 
between bone lead levels (a more sensitive marker for chronic low grade lead 
exposure) and hypertension. 
 Hence an attempt has been made here to study the prevalence of elevated 
blood lead levels in patients with primary hypertension and its correlation with 
hypertensive target organ damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To measure blood lead levels in patients with primary hypertension. 
 
2. To identify whether any association exists between age, sex and target 
organ damage and the presence of elevated blood lead levels. 
 
3. To correlate the results with standard data available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
HYPERTENSION 
 
An elevated arterial pressure is one of the most important public health 
problems and despite its widely recognized high prevalence and associated 
danger, it remains inadequately treated in majority of the patients. It is common, 
readily detectable, and usually easily treatable and if left untreated can lead to 
serious morbidity and mortality from cardiac, cerbrovascular, vascular and renal 
disease. Adequate hypertension control remains elusive because of the 
asymptomatic nature of the disease for the first 15-20 years even as it 
progressively damages the cardiovascular system (Kaplan, 1998). Although our 
understanding of the pathophysiology of hypertension has increased in 90% to 
95% of cases, etiology is still mostly unknown. 
 
Definition and Classification: 
 
Blood pressure is distributed in a typical bell shaped curve within the 
overall population. As seen in the Multiple Risk Factor Intervention Trial 
(MRFIT), the long-term risks for cardiovascular mortality rise progressively over 
the entire range of blood pressure, with no threshold that clearly identifies the 
potential danger. Therefore the definition of hypertension is somewhat arbitrary 
and usually taken as that level of pressure associated with doubling of long term 
risks. As per JNC-7 report Hypertension is defined as systolic B.P ≥ 140mm Hg 
and or diastolic B.P ≥ 90mm Hg. The JNC classification is shown in table 1. 
Table 1 
Category Systolic B.P. (mm of Hg) Diastolic BP (mm of Hg) 
Normal <120 and <80 
Pre-Hypertension 120-139 Or 80-89 
Hypertension 
Stage 1 
Stage 2 
 
140-159 
>160 
 
Or 
Or 
 
90-99 
>100 
 
Prevalence: 
The prevalence of hypertension depends on both the racial composition of 
the population studied and the criteria used to define the condition. In a white 
sub-urban population like that in the Framingham Study, almost one half have 
blood pressure greater than 140/90 mm Hg. In India as per study conducted by 
Gupta  et al in 1977-78, the prevalence was 59.9 and 69.9 per 1000 in males and 
females respectively in urban population and 35.5 and 35.9 per 1000 in males 
and females respectively in  rural population. 
More than 90% of all hypertensives will have no recognizable cause.  
 
The prevalence of various secondary causes of hypertension is shown in 
Table -2 (Rudnick et al) 
                  
Table -2 
                      
Diagnosis Percentage 
Essential Hypertension 94% 
Chronic renal disease 5% 
Reno-vascular disease 0.2% 
Coarctation of aorta 0.2% 
Primary aldosteronism 0.2% 
Pheochromocytoma 0.2% 
OCP-induced hypertension 0.2% 
 
Natural history and Complications: 
 
The pathological hallmark of uncontrolled hypertension is acceleration of 
atherosclerosis. The higher the BP, the more likely that various cardiovascular 
disease will develop prematurely. If untreated, 50% of hypertensive patients die 
of coronary artery disease or congestive cardiac failure, about 33% of stroke and 
10-15% of renal failure. A meta-analysis of nine major prospective studies shows 
a direct continuous and apparently independent association of diastolic BP with 
both coronary artery disease and stroke (MacMohan et al, 1990). The various 
target organ damage due to hypertension is as follows. 
 
                                                
Table 3 
Target Organ Damage 
Heart     
Left ventricular hypertrophy 
Angina or  myocardial infarction 
Heart failure 
 
Brain 
Stroke or transient ischemic attack 
 
Chronic kidney disease 
 
Peripheral arterial disease 
 
Retinopathy 
 
Overall Cardiovascular Risk: 
 
The degree of risk from hypertension can be categorized with reasonable 
accuracy by taking into account 
 
1. The level of Blood Pressure 
2. The presence of target organ damage. 
3. The co-existence of other cardiovascular risk factors. (Jackson, et al 1993) 
 
The goal of anti-hypertensive therapy should not only be reduction of 
blood pressure but also treatment of other risk factors. The major cardiovascular 
risk factors indicated in JNC -7 report are: 
1. Hypertension 
2. Cigarette smoking 
3. Obesity 
4. Physical inactivity 
5. Dyslipidemia 
6. Diabetes mellitus 
7. Microalbuminuria or estimated GFR <60 ml /min 
8. Age (>55 for men, >65 for women) 
9. Family history of premature cardiovascular disease (<55 for men, <65 for 
women) 
Mechanisms of Primary Hypertension: 
 
No single or specific cause is known for most hypertension and the 
condition is referred to as primary in preference to essential. Blood Pressure is 
the product of cardiac output and peripheral vascular resistance (BP = CO × 
PVR) and increase in blood pressure develops in response to factors which 
affects these two forces. The development of the disease is slow and gradual. 
 
Genetic Predisposition: 
 
In studies of twins and family members in which the degree of familial 
aggregation of blood pressure level is compared with closeness of genetic 
sharing, the genetic contributions have been estimated to range from 30% - 60% 
(Harrap,1994). Unquestionably environment plays some role and Harrap (1994) 
offers an interaction between genes and environment as a working model in 
which the average population pressure is determined by environment but the 
blood pressure rank within the distribution is decided by genes. Genetic 
abnormalities may be monogenic as in Liddle syndrome, glucocoriticoid 
remediable aldosteronism and apparent mineralocorticoid excess (Luft, 1998) or 
involves polymorphism of genes involving Renin Angiotension System (Staessen 
et al, 1999), Aldosterone system or adrenergic receptors. 
Fetal Environment: 
 
Low birth weight as a consequence of fetal under nutrition is followed by 
an increased incidence of high blood pressure later in life (Law and Shiell, 1996). 
Brenner and Cherton hypothesized that a decreased number of nephrons from the 
intrauterine growth retardation could very well serve as a permanent irreparable 
defect that eventuates in hypertension (Brenner and Cherton, 1996) 
 
Renal Retention and Excess of Dietary Sodium: 
 
A considerable amount of circumstantial evidence supports a role for sodium 
in the genesis of hypertension. To induce hypertension some of that excess 
sodium must be retained by the kidneys. Such retention could arise in a number 
of ways. 
 • A decrease in the filtration surface by a congenital or acquired deficiency 
in nephron number or function (Brenner, 1992). 
 
• A resetting of pressure-natriuresis relationship (Guyton, 1992) 
 
• An acquired inhibition of the sodium pump (Noolfson et al, 1991). 
• Nephron heterogenecity-presence of a subgroup of nephrons that is 
ischemic either from afferent arteriolar vasoconstriction or from an 
intrinsic narrowing of the lumen (Sealy et al,1998) 
 
Vascular Hypertrophy: 
 
A number of factors increase peripheral resistance by both functional 
contraction and vascular remodeling and hypertrophy. Multiple vasoactive 
substances act as pressure-growth promoters resulting in both vascular 
contraction and hypertrophy, but perpetuation of hypertension involves 
hypertrophy. Lever and Harrp postulated (Lever, Harrp1992) that primary 
hypertension has two mechanisms similar to secondary hypertension (1) a growth 
promoting process in children, (2) a self –perpetuating mechanism in adults. 
 
Neurohumoral Causes of Primary Hypertension: 
 A large number of circulatory hormones may be involved in the 
development of hypertension which causes hypertension by vascular 
hypertrophy, capillary rarefaction and impaired microvascular dilatation (Pries, 
1999). 
 
Sympathetic Nervous Hyperactivity: 
 
Young hypertensives tend to have increased levels of circulating 
catecholamines, augmented sympathetic traffic in muscles, faster heart rate and 
heightened reactivity to α-adrenergic agonists (White et al, 1999). These changes 
raise BP by causing vasoconstriction, increased cardiac output and by altering 
normal renal pressure-volume relationship. 
 
Renin-Angiostension System (RAS): 
 
Both as a direct pressor and as a growth promoter, the RAS mechanism 
may also be involved in the pathogenesis of hypertension. All functions of renin 
are mediated through the synthesis of Angiotension II. This system is the primary 
stimulus for secretion of aldosterone and hence mediates mineralocorticoid 
responses to varying sodium intake and volume overload. When sodium intake 
decreases or plasma volume shrinks the increase in Angiotensin  II stimulates 
aldosterone secretion, which causes retention of sodium and water. Increase in 
blood pressure inhibits release of rennin from kidney by a feed back mechanism. 
Thus primary hypertension would be expected to be accompanied by low renin, 
but only 30% have low renin while 50% have normal levels and 20% have high 
values. (Brunner, et al. 1973). 
Hyperinsulinemia /Insulin resistance: 
 
An association between hypertension and hyper insulinemia has been 
established not only in obese but also in non obese hypertension (Liese et al, 
1998). The hyperinsulinemia of hypertension arises as a consequence of 
resistance to the effects of insulin on peripheral glucose utilization. Insulin has 
multiple pressor effects (Cardillo et al, 1998) including activation of sympathetic 
activity, trophic action on vascular smooth muscle and increased renal sodium 
absorption. Normally the pressor effects are counteracted by insulin mediated 
increased synthesis of nitric oxide. In hypertension there is impairment in the 
insulin mediated increase in nitric oxide leading to rise in blood pressure. 
 
Endothelial Dysfunction 
 
Endothelium is now known to be the source of multiple relaxing and 
contracting substances of which nitric oxide is an important vasodilator 
(Steinberg, et al, 1994). Hypertensive patients have been shown to have impaired 
nitric oxide mediated vasodilatory responses (Ruschitzka, et al, 1998). 
 
 
Other Associated Conditions 
 
Hypertension is associated with other conditions like obesity, physical 
inactivity, sleep apnea, alcohol intake, smoking and hyperuricemia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LEAD 
 
The very word plumbing comes from the Latin word for lead 
plumbum.Symptoms of plumbism or lead poisoning were apparent as early as 1st 
century BC. Worldwide, six sources appear to account for most lead exposure : 
 
1. Gasoline additives 
2. Foodcan soldering 
3. Lead based paints 
4. Ceramic glazes 
5. Drinking water systems   
6. Cosmetics and folk remedies  
 
Source 
 
Lead has been mined and used in industry and in household products for 
centuries. The dangers of lead toxicity, the clinical manifestations of which are 
termed plumbism, have been known since ancient times. The twentieth century 
saw both the greatest ever exposure of the general population to lead and an 
extraordinary amount of new research on lead toxicity. 
Populations are exposed to lead chiefly via paints, cans, plumbing 
fixtures, and leaded gasoline. The intensity of these exposures, while decreased 
by regulatory actions, remains high in some segments of the population because 
of the deterioration of lead paint used in the past and the entrainment of lead 
from paint and vehicle exhaust into soil and house dust. Many other 
environmental sources of exposure exist, such as leafy vegetables grown in lead-
contaminated soil, improperly glazed ceramics, lead crystal, and certain herbal 
folk  remedies. Many industries, such as battery manufacturing, demolition, 
painting and paint removal and ceramics, continue to pose a significant risk of 
lead exposure to workers and surrounding communities. 
 
New research on lead toxicity has been stimulated by advances in 
toxicology and epidemiology as well as by a shift of emphasis in toxicology 
away from binary outcomes(life/death:50% lethal dose) to grades of function, 
such as neuropsychological performance, indices of behavior, blood pressure, 
and kidney function. 
 
Tests for levels of lead in blood have facilitated both research on lead and 
surveillance of individuals at risk. Blood lead is now measured with stringent 
quality controls in commercial laboratories worldwide. Measurement of the 
blood lead levels of children 6 month to 5 years of age in mandated by some 
states, and the U.S Occupational Safety and Health Administration (OSHA) 
requires the testing of workers who may be exposed to lead in the course of their 
jobs. 
 
Metabolism 
 
Elemental lead and inorganic lead compounds are absorbed through 
ingestion or inhalation. Organic lead (e.g., tetraethyl lead, the additive to 
gasoline) is absorbed to a significant degree through the skin as well. Pulmonary 
absorption is efficient, particularly if particle diameters are <1μm (as in fumes 
from burning lead paint). Children absorb up to 50% of the amount of lead 
ingested whereas adults absorb only ~10 to 20%. Gastrointestinal absorption of 
lead is enhanced by fasting and by dietary deficiencies in calcium, iron and zinc; 
such absorption is minimal, however, for lead in the form of lead sulfide, a 
common constituent of mining waste. Lead is absorbed into blood plasma, where 
it equilibrates rapidly with extra cellular fluid, crosses membranes (such as the 
blood-brain barrier and the placenta), and accumulates in soft and hard tissues. In 
the blood ~ 95 to  99% of lead is sequestered in red cells, where it is bound to 
hemoglobin and other components. As a consequence, lead is usually measured 
in whole blood rather than in serum. The largest proportion of absorbed lead is 
incorporated into the skeleton, which contains >90% of the body’s total lead 
burden. Lead also appears in hair, nails, sweat, saliva, and breast milk. The half-
life of lead in blood is ~ 25 days; in soft tissue, ~ 40 days; and in the nonlabile 
portion of bone, >25 years. Thus, blood lead levels may decline significantly 
while the body’s total burden of lead remains heavy. 
 
The toxicity of lead is probably related to its affinity for cell membranes 
and mitochondria, as a result of which it interferes with mitochondrial oxidative 
phosphorylation and sodium, potassium, and calcium ATPases. Lead impairs the 
activity of calcium-dependent intracellular messengers and of brain protein 
kinase C. In addition, lead stimulates the formation of inclusion bodies that may 
translocate the metal into cell nuclei and alter gene expression.  
 
Clinical toxicology  
 
Symptomatic lead poisoning in childhood generally develops at blood lead 
levels>3.9 μmol/L (80μg/dl) and is characterized by abdominal pain and 
irritability followed by lethargy, anorexia, pallor (resulting from anemia), ataxia 
and slurred speech. Convulsions, coma, and death due to generalized cerebral 
edema and renal failure occur in the most severe cases. Sub clinical lead 
poisoning [blood lead level>1.4μmol/L (>30μg/dl] can cause mental retardation 
and selective deficits in language,cognitive function, balance, behaviour, and 
school performance despite the lack of discernible symptoms. Epidemiologic 
studies and meta-analyses of studies regarding lead’s effect on the intellectual 
function of children indicate that cognition is probably impaired in a dose-related 
fashion at blood lead levels well below 1.4 μmol/L  (30 μg/dl) and that no 
threshold for this effect is likely to exist above the lowest measurable blood lead 
level of 0.05 μmol/L . The impact is greatest when the exposure is of long 
duration and has been most apparent when it takes place around the age of 2 
years; however, the impact of fetal lead exposure remains to be clarified, 
particularly in view of the observation that maternal bone lead stores can be 
mobilized to a significant degree during pregnancy, with consequent exposure of 
the fetus. 
 
In adults, symptomatic lead poisoning, which usually develops when 
blood lead levels exceed 3.9μg/dL)  for a period of weeks,is characterized by 
abdominal pain, headache, irritability, joint pain, fatigue, anemia,  peripheral 
motor neuropathy, and deficits in short-term memory and the ability to 
concentrate. Encephalopathy is rare. A “lead line” sometimes appears at the 
gingival-tooth border after prolonged high level exposure. Some individuals 
develop these symptoms and signs at lower blood lead levels [1.9 to 3.9 μmol/L 
(40 to 80μg/dL)] and or with briefer periods of exposure. Chronic sub clinical 
lead exposure is associated with interstitial nephritis, tubular damage (with 
tubular inclusion bodies), hyperuricemia (with an increased risk of gout), and a 
decline in glomerular filtration rate and chronic renal failure. Epidemiologic 
evidence also suggests that blood lead levels in the range of 0.34 to 1.7 μmol/L 
(7to 35 μg/dL) are associated with increases in blood pressure, decreases in 
creatinine clearance, and decrements in cognitive performance that are too small 
to be detected as a lead effect in individual cases but nevertheless may contribute 
significantly to the causation of chronic disease. 
 
An additional issue for both children and adults is whether lead that has 
accumulated in bone and lain dormant for years can pose a threat later in life, 
particularly at times of increased bone resorption such as pregnancy, lactation, 
and senile osteoporosis. Elevation of the bone lead level appears to be a risk 
factor for anemia, hypertension, cardiac conduction delays, and impairment of 
cognitive function. Hyperthyroidsm has been reported to cause lead toxicity in 
adults by mobilizing stores of bone lead acquired during childhood. 
 
 
 
Genetic polymorphisms, such as variants of the gene that codes for 
aminolevulinic acid dehydratase(a critical enzyme in the production of heme) or 
the C282Y hemochromatosis gene,may confer differences in susceptibility to 
lead retention and toxicity; ~ 15% of  Caucasians have a variant form of one of 
these genes. This issue is the focus of continued research. 
 
Laboratory findings 
 
In 1991, the Centers for Disease Control and Prevention designated 0.48 
μmol/L(10µg/dL) as the blood lead level of concern in children. A specific set of 
interventions is recommended when the level exceeds this value. OSHA requires 
the regular measurement of blood lead in lead-exposed workers and the 
maintenance of blood lead <1.9 μmol/L             (40 μg/dL). Concentrations of 
heme precursors (such as δ-aminolevulinic acid) in plasma and urine are 
sometimes increased at blood lead levels as low as 0.73 μmol/L (15μg/dL). 
Levels of protoporphyrin (free erythrocyte or zinc )rise –although not 
consistenly- once blood lead levels have exceeded  1.2 μmol/L (25μg/dL) for 
several months. Lead associated anemia is usually normocytic and 
normochromic and may be accompanied by basophilic stippling. Lead–induced 
peripheral demyelination is reflected by prolonged nerve conduction time and 
subsequent paralysis, usually of the extensor muscles of the hands and feet (wrist 
drop and foot drop). An increased density at the metaphyseal plate of growing 
long bones (lead lines) can develop in children and resemble those seen in 
rickets. Children with high-level lead exposure sometimes develop Fanconi’s 
syndrome, pyuria, and azotemia. Adults chronically exposed to lead can develop 
elevated serum creatinine levels, decreased creatinine clearance rates, and 
chronic changes and intranuclear inclusion bodies (detected at renal biopsy). 
Deficits may be apparent in neuropsychometric tests of both children and adults; 
these abnormalities by themselves are not pathognomonic. Bone lead levels 
measured in vivo by K-x-ray fluorescence, a technique adapted for this purpose, 
are more sensitive than blood levels as a predictor of hypertension, cognitive 
impairments, and reproductive toxicity in epidemiologic studies; however, 
measurement of bone lead levels has not been shown to be of clinical value and 
is not widely available.  
 
Treatment 
 
It is absolutely essential to prevent further exposure of affected individuals 
to lead. Cases of lead poisoning should be reported to local boards of health so 
that home evaluations can be performed. Pharmacologic treatment for lead 
toxicity entails the use of chelating agents, principally edetate calcium (Ca 
EDTA), dimercaprol, penicillamine, and succimer, which is given orally and has 
relatively few side effects. Chelation is recommended for the treatment of all 
children whose blood lead levels are >2.7 μmol/L (55 μg/dL) with the addition of 
dimercaprol if lead encephalopathy is found. Chelation is also recommended for 
children if blood lead levels are between 1.2 and 2.7 μmol/L (25 and 55 μg/dL) 
and the total amount of lead excreted in urine during the 8 h after a single dose of 
edetate calcium disodium exceeds 9.7 μmol/L (200 μg/dL). Chelation is 
recommended for adults if blood lead levels exceed 3.9 μmol/L (80 μg/dL) or if 
greater than 2.9 μmol/L (60 μg/dL) in symptomatic individuals. The ability of 
chelation to improve subclinical outcomes (such as performance on psychometric 
testing) at lower levels of blood lead in both children and adults is the subject of 
current research. 
 
In developed countries lead poisoning is not prevalent; however in 
developing countries lead poisoning is extremely common, to such an extent that 
world wide lead toxicity and poisoning remains the most common of 
occupational poisonings. Developed countries like the US, UK and Germany 
have taken aggressive steps to combat lead poisoning. In developing countries 
however, actions have been slower and sporadic. Within the last decade, reports 
of lead poisoning in humans have poured in particularly from the developing 
countries faced with environmental and occupational lead exposure. 
 
In India, as in most developing countries, the main source of lead 
pollution is automobile exhaust; although India issued in February 1990 its first 
National emission standards for lead and other pollutants, the recommended 
permissible limits of lead (0.56g/L) are still very much higher the those of 
developed countries. 
 
 
 
 
 
 
  
 
 
 
 
 
 
HYPERTENSION AND LEAD 
 
The significant role of lead in hypertension is rapidly evolving. Studies by 
the environmental protection agency, as well as other international regulatory 
agencies, have shown that chronic low level exposure to lead is associated with 
societal problems such as brain dysfunction in children exposed to lead in 
drinking water, renal changes in adults, hypertension and chronic kidney 
disease.(Brautbar et al 1995,Telisman S et al 2004,Sirivarasai et al 2004). 
Potential effects on adult blood pressure have been described in populations 
encountering common environmental  concentrations ( Beevers et al 1976) .Other 
published studies (Annest J L et al, 1983) have shown that blood lead levels were 
related to ambient environmental exposures(Beevers et al 1980, Bost L et al 
1999). Those studies showed a direct relationship between blood pressure 
elevation and low level toxicological exposure to lead without the classical 
presentation of lead toxicity (Annest J L et al, 1983). A study in the United States 
looked at the relationship between blood lead level and high blood pressure and 
found a direct relationship between blood lead levels and systolic and diastolic 
blood pressure for men and women, and that blood levels of lead were 
significantly higher in younger men and women with high blood pressures 
(Harlan W R 1985). Beevers et al (1980), in an interesting study found that blood 
lead levels correlate with hypertension in persons exposed to hard water and not 
in those exposed to soft water. They concluded that low grade exposure from 
water leads to increased blood lead levels and hypertension. 
 
It is of importance to note that in all of these studies the blood pressure 
was correlated with slightly elevated lead levels which have been considered to 
be “safe” and are the result of low level cumulative exposure to lead. These 
studies indicate very clearly that blood lead levels were found to contribute 
independently to the elevation of systolic and diastolic hypertension. In some 
studies bone lead levels were used to measure chronic low level exposure to lead 
and were found to be elevated in hypertensives. (Cheng et al , 2001) (Stassen et 
al 1992). 
 
Multiple sources of exposure exist including occupational, ambient 
environmental and consumption of water from lead piping which all contribute to 
elevation of blood lead levels .Most thinking about lead exposure and 
hypertension has usually been directed towards excessive occupational exposure 
and effects of lead and kidney function, kidney compromise and in turn, effects 
on high blood pressure. In a study Lee (1996) found that each 10 fold increase in 
blood lead level was associated with a serum creatinine increase of 0.08mg/dL. 
 
Tsaih et al 2004, says that longitudinal decline of renal function among 
middle aged and elderly individuals appears to depend on both long-term lead 
stores and circulating lead. Other studies also concentrate on lead induced 
nephrotoxicity and hypertension (Pirkle et al, 1985) (Hu H ,2000) (Batuman V, 
1993). 
 
There is more and more evidence that chronic low level toxicological 
exposure to lead has both direct and indirect effects on the blood vessel and its 
smooth muscle’s contractility and thereby affecting the blood pressure.  
 
Some authors find no statistically significant difference in blood lead 
levels with respect to target organ damage like left ventricular hypertrophy 
(Tepper et al 2001) 
 
Mechanism of lead induced hypertension 
 
Chronic lead exposure basically targets catecholamine and nitric oxide 
systems in inducing selective functional impairment. Cormignani etal (2000) 
have conducted a study in which rats were exposed for ten months to 60 ppm of 
lead (Pb acetate) in drinking water and the cardiovascular effects of chronic lead 
were assessed. At the end of treatment, mean lead levels were increased in lead 
exposed rats. The conclusions derived from their study were: 
 
1. Lead increases plasma levels of noradrenaline and adrenaline  
2. Lead increases monoamine oxidase  activity in aorta and liver 
3. Plasma level of nitric oxide decreases  
4. Increases peripheral resistance, cardiac inotropism 
5. Increases cAMP dependent availability  of Ca  ions for contractile 
mechanism in vascular and cardiac myocells 
6. Also increases vascular alpha-2 and myocardial B1 adreno receptor  
reactivity 
7. Also inhibits Kallikrein- Kinin and RAA systems  
 
It was thus concluded that lead appeared to increase sympathetic activity 
both by central and peripheral mechanisms .Sharifi et al (2004) have conducted a 
similar study in rats and proposed several mechanisms to explain lead induced 
hypertension. They have investigated the etiological role of RAS and ACE 
activity in this context. This study also revealed that BP gradually increases in 
correlation with lead exposure. There was also a significant increase of local and 
serum ACE activity in the early phase of lead exposure thus emphasizing the 
etiological role of ACE activity in lead induced hypertension. 
Various similar studies have been conducted in humans to find out the 
effects of chronic low level lead exposure in the causation of hypertension. A 
study was conducted by Schwartz et al (2000) in former organolead 
manufacturing workers to determine the influence of blood lead, DMSA, (meso 
2,3-dimercapto succinic acid) chelatable lead and tibial lead on systolic and 
diastolic blood pressure. They found that blood lead was a predictor of both 
systolic and diastolic blood pressure and hypertensive status in men less than 58 
yrs. 
 
Thus the pathogenesis of lead induced hypertension in multifactorial 
including such diverse mechanisms as  
• Inactivation of endogenous nitric oxide. (Vaziri et al, 2004; Apostoli et al, 
2004) 
• Down regulation of soluble guanylate cyclase by reactive oxygen species 
leading to functional deficiency of nitric oxide. 
• Heightened sympathetic activity and plasma noradrealine. 
• Decreased vascular and increased renal beta adreno receptor density (Chang 
H R, 2005) 
• Increased plasma ACE activity, plasma renin activity, angiotensin II and 
aldosterone level 
• Increased  kininase I and kininase II activites . 
 
• Lead induced inhibition of vascular smooth muscle Na K ATPase causing 
increased cellular Na+ ,Ca2+ 
• Possible increase in endothelin and TXA2 generation  
• Increase in vasoconstrictive prostaglandins and decrease in vasodilatory 
prostaglandins. 
 
From the review the following conclusions were arrived at : 
 
The available scientifically reviewed data described above shows that 
exposure to low levels of lead on a repetitive basis in some population and in 
some patients can be associated with high blood pressure. These issues of high 
blood pressure and neurobehavioral charges in relation to lead exposure are 
commonly missed, not looked for in patients who present with low level 
toxicological exposure to lead. There is little controversy regarding the issue that 
lead levels is clinically significant and relevant although its role as an 
independent risk factor in the causation of hypertension may be controversial. 
 
From a clinical standpoint, a practising doctor should not forget the 
concept of low level toxicological exposure to lead. He should not always 
concentrate on the classic presentation of lead toxicity. A prudent physician has 
to take into account and address the issue of environmental lead exposure while 
treating patients. 
The current focus of attention is on the subclinical effects of exposure. 
There is pressure to reduce lead exposure in general population and in working 
environment (Gidlow DA2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
 
Setting                          : Government Rajaji Hospital and  
                                          Madurai Medical College, Madurai   
                                                                                                                                                              
Collaborating               : School of Energy Sciences 
Department                   : Department of Environment 
                                          Madurai Kamaraj University, Madurai 
 
Study Design      : Case control study 
Period of Study     : August 2004 to August 2005 
Sample Size      : 60 Subjects 
Ethical committee        : The present project was approved by the approval
       ethical committee 
                                   
 
Inclusion criteria: 
Cases:  
1. Newly diagnosed drug naïve hypertensive  patients attending Out 
patient(O.P) clinic .      
2. Patients between ages 30-50yrs. 
3. Both sexes. 
 Controls:  
           Other patients of the same age group attending the O.P clinic. 
 
Exclusion criteria: 
1. Individuals less than 30 and more than 50years  
2. Patients with renal failure and diabetes mellitus  
3. Pregnant women. 
4. Patients with secondary hypertension 
5. Patients who were already on antihypertensive therapy 
6. Postmenopausal women 
7. Patients exposed to certain occupations, industries where lead 
concentration is high (e-g) painters, plumbers etc. 
Controls  
 
Subject whose ages were between 30 yrs and 50 yrs and had normal blood 
pressure. 
 
Consent 
 
The study group thus identified by the above criteria (inclusion and 
exclusion criteria) were first briefed about the nature of the study. Willing 
participants were taken up after getting a written informed consent from them. 
Materials  
 Thus a total of 30 cases who satisfied the inclusion and exclusion criteria 
above were taken up for the study. 30 age and sex matched subjects were kept as 
controls. 
 
Conflict of interest 
There was no conflict of interest 
 
Financial support 
Nil 
 
Limitations 
1. Only drug naïve newly diagnosed hypertensive patients were included in 
the study. Patients who were already on antihypertensive drugs were not 
studied. 
 
2. Due to technical, financial and ethical constraints, blood lead levels of 
only 30 cases and 30 controls could be measured. 
 
3. Only blood lead levels were measured. Bone lead levels, which is the most 
valuable measure of internal dose (as it represents cumulative exposure) 
and which is a more accurate and sensitive marker to assess chronic low 
level  environmental pollution was not done. Currently the most effective 
method to measure bone lead involves in-vivo K-X-ray fluorescence 
which is expensive and time consuming. It is not practical for studies and 
hence was not done. 
 
4. Due to literary constraints, original copy of all the articles could not be 
obtained. Only abstracts of those articles were obtained. 
 
5. Cigarette smoking and urbanization as confounding factors were not 
eliminated. 
 
6. It is only a cross sectional study. Long term follow up was not done.  
 
7. Vancouver’s method of Bibliography was not followed. Instead Harvard 
method was followed.  
 
Methods: 
Selected socio-demographic, clinical and laboratory data were elicited 
from the patients and controls and recorded in a proforma (enclosed in Annexure 
–annexure I) 
I. Socio –demographic data 
Age 
Sex 
 II. Clinical data      
Systolic and diastolic blood pressure 
Clinical examination 
 
III. Laboratory data 
Blood urea            : Estimation done manually using Diacetyl 
                                                            Monoxime (DAM) technique. 
Serum Creatinine  : Estimation done using COBAS autoanalyser 
 
Blood lead levels  : Measured using atomic absorption Spectro 
                                            Photometry             
 
IV. Statistical Analysis 
 
Data was entered in Microsoft excel spread sheet and analyzed statistically 
using standard statistical software (Epidemiological information package 2002). 
Student ‘t’ values was applied for significance. Significance was considered if 
the ‘p’ value was below 0.01. 
DEFINITIONS USED IN THE PRESENT STUDY  
Essential Hypertension 
 
Hypertension was defined in accordance to the JNC-VII report as systolic 
blood pressure 140 mmHg and above and or diastolic blood pressure 90mm Hg 
above. 
 
In newly detected cases it was the mean of 3 relaxed, seated right arm 
readings. The diagnosis that the hypertension is essential and not secondary was 
made on the overall clinical impression only. Laboratory investigations to rule 
out secondary causes was not done in each case. 
 
Diabetes mellitus 
 
• Already a known case of diabetes mellitus on treatment 
• Fasting plasma glucose  ≥126 mg/dl 
• Two hour plasma glucose ≥200mg/dl 
• Symptoms of diabetes plus random blood glucose >200 mg/dl 
 
Left ventricular hypertrophy 
Based on electrocardiographic findings satisfying either Sokolow-Lyon 
criteria or Cornell Voltiye criteria (Sokolow, Lyon,1949) (Casale, et.al,1987). 
 
Hypertensive retinopathy 
Based on Keith- Wagener-Barker classification of fundoscopic changes. 
RESULTS 
 
The total number of subjects included in this study was 60.Among these 
60 subjects, 30 were cases (hypertensive) and 30 were control (normotensive) 
 
Table – 1 
Age distribution of cases and controls 
 
 Cases Controls 
Age group No % No % 
30-40 5 16.6 7 23.3 
40-50 25 83.4 23 76.7 
Total 30 100 30 100 
Mean age 45.9  43  
SD 5.73  4.24  
 
p value  = 0.0325  
 
This table compares the mean age of cases and controls. There is no 
statistically significant difference in the ages of cases of controls. Hence the 
study is matched for age. 
 
Table – 2 
Sex distribution of cases and controls 
 
 Cases Controls 
Sex No % No % 
Male 19 63.3 18 60 
Female 11 36.7 12 40 
Total 30 100 30 100 
 
 
This table compares the sex distribution in cases and controls. There is no 
significant difference in the distribution with respect to sex. 
 
 
 
 
 
 
 
 
 
 
 
 
Table – 3 
                                 Blood Pressure  Distribution among cases 
 
BP Cases 
 Mean          mm/Hg SD 
Systolic 166.66 25.37 
Diastolic 105.33 16.55 
 The mean and standard deviation for systolic blood pressure among cases 
were 166.66 and 25.37 respectively. Similarly for diastolic blood pressure the 
mean and S.D among cases were 105.33 and 16.55 respectively. 
 
 
  
 
 
 
 
 
 
 
 
Table – 4 
Distribution of cases and controls in relation to smoking 
 
 Cases Controls 
 No % No % 
Yes 13 43.3 14 46.6 
No 17 56.67 16 53.4 
Total 30 100 30 100 
 
In the study population the distribution of smoking is not significantly 
different among cases of controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table – 5 
Distribution of cases and controls with respect to  
Target Organ Damage (TOD) 
 
TOD Cases 
 No Percentage 
LVH  Yes 12 40 
 No 18 60 
IHD  Yes 2 6.3 
 No 28 93.7 
HPR  Yes 6 20 
 No 24 80 
 
The details of prevalence of target organ damage TOD among cases [left 
ventricular hypertrophy (LVH), Ischemic heart disease (IHD) and hypertensive 
retinopathy HTR] are given. 
 
Analysis of cases with respect to target organ damage revealed the 
presence of various target organ damage in the form of 
 
Left ventricular hypertrophy LVH (n=12 ;  40%) 
Ischemic heart disease IHD (n=2 ; 6.3%) 
And hypertensive retinopathy (n=6; 20%) 
 
Table – 6 
Distribution of cases and controls with respect to  
biochemical parameters 
 
Cases Controls Blood 
parameters Mean SD Mean SD 
P 
Bl.sugar 103.8 21.9 86.2 ± 6.20 0.000101 
Urea 27.36 4.48 24.93 ± 2.40 0.0126 
Creatinine 0.80 0.09 0.78 ± 0.08 0.3748 
 
There is a statistically significant difference in cases and control with 
respect to blood sugar and urea. This may be due to high comorbidity of impaired 
glucose tolerance in hypertensives.  But with respect to creatinine which is more 
sensitive marker for renal function and also could be a confounding factor in 
hypertension, there is no statistically significant difference between cases and 
controls. Hence, there is no much difference with respect to renal function 
between cases to controls.  
 
 
 
 
 
 
Table – 7 
Distribution of cases and controls in relation to blood lead levels 
 
Cases Controls 
 
Mean SD Mean SD 
p value 
Bl.Pb 
levels 
µg/dl 
25.34 ± 7.59 7.36 ± 3.62 0.0000001 
 
Using students ‘t’ test P value <0.01 t=11.5 df 58 
 
The mean blood level is 25.34 µg/dl (SD 7.59) in cases and 7.36 µg/dl (SD 
3.62) in controls. This table clearly shows that blood lead level is significantly 
higher in hypertensive patients. 
 
 
 
 
 
 
 
 
 
 
 
Table – 8 
Distribution of blood lead levels ≥10 µg /dl in cases and controls 
 
Cases Controls 
 
No % Mean SD No % Mean SD 
Bl.Pb 
levels≥10 
µg/dl 
 
30 100 25.34 ±7.59 11 36.7 11.4 ±1.22 
 
P=0.0000001  
 As a blood lead level of 10μg/dL is defined as the level of concern by 
many authorities, (Hu et al, 2001) the distribution of blood lead level ≥10μg/dL 
was sought. 
 
All cases had blood lead level ≥ 10μg/dL while 11 (36.7%) controls had 
blood lead level ≥10μg/dL. All these controls were found to be smokers. Hence 
this explains increased blood lead levels in them. Using students ‘t’ test p was 
found to be < 0.01. 
 
Hence the prevalence of high blood lead level above the level of concern 
is statistically high in cases than in controls. 
 
Table – 9 
Mean Pb levels in relation to sex 
 Cases Controls  
 Pb levels (μg/dL) Pb levels (μg/dL)  
Sex No Mean SD No Mean SD  
M 19 27.73 ± 7.69 18 9.32 ± 3.21 
t=9.3325 
df 35 
P=0.0000001 
F 11 21.21 ± 5.58 12 4.41 ± 1.73 
t=9.1303 
df 21 
P=0.00000001 
   
t=2.5775 
df 28 
P=0.01 
  
t=5.234 
df 28 
P=0.0000144 
 
 
From the table it can be seen that in both cases and controls there is 
statistically significant difference in blood lead levels between males and 
females. 
 
This could be due to the effect of smoking on blood lead levels. 
 
But compared with controls in either sex the cases have statistically 
significant high values in blood lead levels. 
 
Table – 10 
Smoking and Blood lead levels 
Blood lead level in μg/dL 
 Cases Controls  
Smoking No Mean SD No Mean SD  
Yes 13 30.55 7.68 14 10.7 1.75 
t=8.7840 
df 35 
P=0.000001 
No 17 21.36 4.62 16 4.36 1.49 
t=13.964 
df 31 
P=0.0000001 
   t=3.51 
df 23 
  t=10.2367 
df 28 
 
P=0.001 P0.0000001 
 
 
 
This table clearly shows that there is statistically significant difference in 
blood lead levels among smokers and non smokers. 
 
In cases (p = 0.01) as well as in controls (p < 0.001) smoking is associated 
with high blood lead levels. 
 
 
 
Table – 11 
Blood lead levels with respect to target organ damage TOD 
 
The mean blood lead levels and standard deviation for cases with and 
without target organ damage is given below. 
 
TOD  No Mean 
(μg/dL) 
SD P 
LVH Yes 12 29.69 ± 7.80 0.014 
[df 28 
t =2.61] 
 No 18 22.45 ± 6.06  
IHD Yes 2 27.35 ± 3.74 0.5962 
[df 28 
t =0.53] 
 No 28 25.20 ± 7.81  
Retinopathy Yes 6 31.61 ± 9.53 0.0898 
[df 28 
t =1.757] 
 No 24 23.77 ± 6.33  
 
 
With regards to target organ damage, though there is some increase in 
blood lead levels in those with target organ damage compared to those without, 
the difference is not statistically significant. 
 
(P values were 0.014, 0.59, 0.08 respectively with reference to LVH, IHD 
& HTR). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
DISCUSSION 
 
Hypertension, the most common form of cardiovascular diseases, is one of 
the most important risk factors for significant morbidity  and mortality in human 
race. Though the cause of essential hypertension is elusive, lead is associated 
with hypertension. 
 
A number of studies have found that increased blood lead levels strongly 
correlate with increased systolic as well as diastolic blood pressure (Brautbar et 
al, 1995; Telisman et al, 2004; Sirivarasai et al, 2004). 
 
In addition chronic low level exposure to lead causes increased blood 
pressure without overt manifestations of lead toxicity (Annest J.L. et al ,1983; 
Harlan WR et al, 1985) 
 
Tepper et al,( 2001) also found increased blood lead levels in hypertensive 
patients compared to normotensives. 
 
Sirivarasai (2004) in a study of 212 men found that an increase in blood 
pressure was significantly predictive of increasing blood lead (p<0.001) 
Similar to those studies, in our study, the mean lead value was 25.34 µg/dl 
±7.59 among cases and 7.36 µg/dl ± 3.62 among controls. Thus there is 
statistically significant increase in blood lead levels in hypertensives compared to 
normotensives in our study. 
 
Some studies found a correlation between blood lead levels and 
hypertension only in selected populations. 
 
Vupputuri et al (2003) found high blood level only in hypertensive black 
men.  
 
Beevers et al in 1980, found a positive correlation between blood lead 
level and hypertension in an environmental survey, though this effect was seen 
only in persons exposed to water with high lead level. Hence he concluded that 
cumulative exposure of lead from drinking water is a source of hypertension. 
 
In our study due to technical constraints, the effect of lead present in 
drinking water on blood lead levels could not be studied. 
 
In some studies blood lead levels do not correlate with hypertension. 
Cheng et al (2001) and Telisman et al (2004) found no correlation between blood 
lead levels and hypertension .But they have found strong correlation between 
bone lead level (which measures chronic low grade exposure ) and hypertension 
.But those studies were done in developed countries. Exposure to lead and hence 
blood lead level vary greatly between countries depending upon the environment. 
 
The mean blood lead value was 25.34 µg/dl for cases and 7.36 µg/dl for 
controls in our study. When we compare this with  other studies this is higher. In 
Vupputuri et al (2003) study the  mean blood lead value was 5.4 ± 0.2 for men 
and 3.4 ± 0.1 for women.. Schwartz  et al (2000) also found increased blood 
pressure in patients with blood lead level as low as 5 µg/dl. 
 
High values in our study could be due to high exposure to lead in 
developing countries in the form of smoke, industrial waste and through water 
(Beevers et al, 1980). But in developed countries the blood lead levels are 
coming down due to  increasing awareness (Vupputuri et al, 2003). 
 
The percentage of persons above blood lead level 10 µg/dl in cases 
is100% where as in controls it is 36.7%. All those controls were smokers. 
Though absolutely no blood lead level is safe, many authorities have defined a 
level of 10 µg/dl as a value of concern (Hu 2001).Hence it  can be said that 
hypertensive patients have blood lead level above the level of concern. 
 
In our study, there is also a significant sex difference in blood lead levels .  
From table 9 it is seen that in both cases and controls, males have high blood lead 
values than controls. This is similar to the studies  of Vupputuri et al( 2003 
)(Men 5.4±0.2 women 3.4±0.1 p<0.001). The difference could be due to many 
factors. Men are more exposed to smoke, industrial pollution, automobile exhaust 
etc., than women. The values are still higher  in developing countries due to men 
exposed to higher level of environmental lead. 
 
Cigarette contains lead and cigarette smoking may contribute significantly 
to increased blood lead levels. Table 10 shows that in both cases and controls 
there is statistically significant difference in blood lead levels among smokers 
and non smokers. Smoking is a risk factor for adverse coronary events. The 
elevation of blood lead level and indirectly of blood pressure may be one of the 
mechanisms of action of cigarette smoking causing atherosclerosis. 
 
 
With reference to target organ damage, in our study, there was a slight 
increase in blood level among those with target organ damage compared with 
those who do not. The difference , however, is not statistically significant. 
Tepper et al (2001) has similar findings in his study. There was no convincing 
evidence of association between lead and other blood pressure related outcomes 
in his study, though there was an effect of blood lead on blood pressure. 
 
Blood pressure is clearly increased by high blood lead levels in our study. 
Blood lead level is increased by chronic low grade exposure and  the 
prohypertensive effect of lead occurs at blood lead levels which are very much 
below those that are associated with clinically significant symptoms like 
neurological behavioral manifestations.Hence the need to identify patients 
exposed to sub threshold values becomes important. This is much more 
important in developing countries with high environmental exposure and less 
rigid pollution control measures. Identifying & intervening hypertensives with 
high lead levels at an early stage may halt the progress of a debilitating illness. 
 
Measurement of lead exposure can be difficult as more accurate methods 
like measuring bone-lead levels are not available freely. More studies in this area 
and more prospective studies with respect to outcome measures are the need of 
the hour. 
CONCLUSIONS 
 
1. Blood lead level was significantly elevated in persons with hypertension 
(Mean 25.34±7.59 μg/dL) than normotensive controls (Mean 7.36±3.62 
μg/dL). 
 
2. Blood lead level was ≥ 10 μg/dL in all the cases(100%).In controls it was 
36.7%. Blood lead level of 10μg/dL is defined as the value of concern by 
many. 
 
3. There is a statistically significant difference between males & females with 
respect to blood lead values in both cases and controls.  
Cases  :  Males → 27.73 ± 7.69  μg/dL   ;  Females →  21.21 ± 5.58 μg/dL 
  Controls :   Males → 9.32 ± 3.21 μg/dL ;  Females → 4.41 ± 1.73 μg/dL 
 
4. There is a statistically significant difference between smokers and non-
smokers with respect to blood lead levels in both cases as well as controls. 
 
 Cases: Smokers → 30.55 ± 7.68 μg/dL ; Non Smokers →  21.36 ± 4.62 μg/dL 
  Controls: Smokers → 10.7 ± 1.75 μg/dL    ; Non Smokers → 4.36 ± 1.49 μg/dL 
 
5. Blood lead levels were not significantly elevated in patients with target organ 
damage compared to those without. 
 
SUMMARY 
 
Blood lead level strongly correlates with hypertension. The present study 
was aimed to study the blood lead level in patients with primary hypertension 
and to find out its association with sex, smoking status and target organ damage. 
With rigid criteria 30 patients were selected and evaluated on social, clinical and 
laboratory aspects after institutional ethical clearance with an informed consent. 
The data were entered in computer and analyzed statistically. 
 
The controls were matched for age and sex compared to cases. There were 
19 males and 11 females in the case group and 18 and 12 respectively in control 
group. The mean systolic BP was 166.66 mmHg and 105.33mmHg  diastolic. 
 
The mean lead levels were significantly higher in hypertensives (Mean 
25.34 ±7.59 μg/dL) compared to controls (7.36±3.62 μg/dL). The percentage of 
persons with blood lead levels > 10 μg/dL is also greater in cases than in controls 
(100% Vs 36.7%). There is also a statistically significant difference in blood lead 
values among smokers and non smokers in both cases and controls. (Cases 
:smokers 30.55 ± 7.68 μg/dL non smokers 21.36 ± 4.62 μg/dL; Controls : 
smokers 10.7 ± 1.75 μg/dL, non smokers 4.36±1.49 μg/dL). There is also a 
statistically significant difference between males and females in both cases and 
controls [Cases: males 27.73±7.69 μg/dL; females 21.21 ± 5.58 μg/dL ;Controls 
:males 9.32 ± 3.21 μg/dL ;females 4.41 ± 1.73 μg/dL]. 
 
The percentage of those with target organ damage were 40%, 6.3% and 
20% respectively for LVH, IHD and retinopathy. There is no correlation between 
increased blood level between those with and without target organ damage. 
 
Animal & human studies have found correlation between blood lead levels 
and hypertension. In view of the increased industrialization and poor 
environmental surveillance, it is prudent to explore blood lead levels in 
hypertensives especially those with chronic low grade exposure. 
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PROFORMA 
Name :     Age:  Sex:  Occupation: 
Presenting Complaints :   Duration: 
Chest Pain 
Breathlessness 
Palpitation 
Giddiness 
Headache 
Smoking 
Physical  examination : 
Anemia  Cyanosis Pedal edema   JVP 
PR  BP  Fundus 
Systemic Examination 
CVS : Apical impulse position  
Character 
Thrill / Murmur 
S1S2 
A2 intensity 
RS 
P/A 
CNS 
INVESTIGATIONS 
 
Blood Sugar     ECG 
Urea 
Serum Creatinine 
X-ray Chest PA view   Blood Lead Levels 
 
 
